NASDAQ:CPIX - Cumberland Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.50 +0.60 (+10.17 %) (As of 03/22/2019 04:00 PM ET)Previous Close$6.50Today's Range$5.92 - $6.5052-Week Range$5.03 - $7.29Volume5,221 shsAverage Volume10,887 shsMarket Capitalization$100.43 millionP/E Ratio-54.17Dividend YieldN/ABeta0.29 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, together with its subsidiaries, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. Its marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for the treatment of chronic and acute constipation; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Ethyol (amifostine) for injection to treat oncology patients; and Totect Injection for the treatment of toxic effects. The company's product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. Its pre-approval products consist of RediTrexTM Methotrexate injection for treating active rheumatoid, juvenile idiopathic, and psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc and Nordic Group B.V. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee. Receive CPIX News and Ratings via Email Sign-up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:CPIX Previous Symbol CUSIP23077010 CIK1087294 Webwww.cumberlandpharma.com Phone615-255-0068Debt Debt-to-Equity Ratio0.36 Current Ratio2.13 Quick Ratio1.69Price-To-Earnings Trailing P/E Ratio-54.17 Forward P/E Ratio-27.08 P/E GrowthN/A Sales & Book Value Annual Sales$40.74 million Price / Sales2.47 Cash Flow$0.0824 per share Price / Cash Flow78.91 Book Value$3.58 per share Price / Book1.82Profitability EPS (Most Recent Fiscal Year)($0.12) Net Income$-6,960,000.00 Net Margins-17.09% Return on Equity-3.08% Return on Assets-1.89%Miscellaneous EmployeesN/A Outstanding Shares15,450,000Market Cap$100.43 million Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Cumberland Pharmaceuticals (NASDAQ:CPIX) Frequently Asked Questions What is Cumberland Pharmaceuticals' stock symbol? Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX." How were Cumberland Pharmaceuticals' earnings last quarter? Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) posted its quarterly earnings results on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.14. The specialty pharmaceutical company had revenue of $8.49 million for the quarter, compared to analyst estimates of $9.16 million. Cumberland Pharmaceuticals had a negative return on equity of 3.08% and a negative net margin of 17.09%. View Cumberland Pharmaceuticals' Earnings History. When is Cumberland Pharmaceuticals' next earnings date? Cumberland Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Cumberland Pharmaceuticals. What price target have analysts set for CPIX? 1 brokerages have issued 12 month price targets for Cumberland Pharmaceuticals' shares. Their predictions range from $8.75 to $8.75. On average, they anticipate Cumberland Pharmaceuticals' share price to reach $8.75 in the next year. This suggests a possible upside of 34.6% from the stock's current price. View Analyst Price Targets for Cumberland Pharmaceuticals. What is the consensus analysts' recommendation for Cumberland Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cumberland Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cumberland Pharmaceuticals. Has Cumberland Pharmaceuticals been receiving favorable news coverage? News headlines about CPIX stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cumberland Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. Who are some of Cumberland Pharmaceuticals' key competitors? Some companies that are related to Cumberland Pharmaceuticals include ImmunoGen (IMGN), Karyopharm Therapeutics (KPTI), Keryx Biopharmaceuticals (KERX), Kindred Biosciences (KIN), Albireo Pharma (ALBO), MediciNova (MNOV), Osmotica Pharmaceuticals (OSMT), Urovant Sciences (UROV), Insys Therapeutics (INSY), Kezar Life Sciences (KZR), American Brivision (Holding) (ABVC), Protagonist Therapeutics (PTGX), Verrica Pharmaceuticals (VRCA), Geron (GERN) and Syros Pharmaceuticals (SYRS). What other stocks do shareholders of Cumberland Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include Vanda Pharmaceuticals (VNDA), Fate Therapeutics (FATE), Protalix Biotherapeutics (PLX), Rigel Pharmaceuticals (RIGL), Madrigal Pharmaceuticals (MDGL), Allena Pharmaceuticals (ALNA), Catalyst Pharmaceuticals (CPRX), Synergy Pharmaceuticals (SGYP), Dicerna Pharmaceuticals (DRNA) and Rockwell Medical (RMTI). Who are Cumberland Pharmaceuticals' key executives? Cumberland Pharmaceuticals' management team includes the folowing people: Mr. A. J. Kazimi, Founder, Chairman, CEO & Pres (Age 61)Mr. Michael P. Bonner, CFO & Sr. Director of Fin. & Accounting (Age 42)Mr. Leo B. Pavliv, Chief Devel. Officer & Exec. VP of Operations (Age 58)Mr. James Lowrance Herman, Chief Compliance Officer & Sr. VP of National Accounts (Age 64)Mr. Martin E. Cearnal, Exec. VP, Chief Commercial Officer & Director (Age 74) Who are Cumberland Pharmaceuticals' major shareholders? Cumberland Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (8.46%), Dimensional Fund Advisors LP (5.67%), Dimensional Fund Advisors LP (5.67%) and BlackRock Inc. (1.98%). Company insiders that own Cumberland Pharmaceuticals stock include Kenneth Krogulski, Michael Bonner and Thomas R Lawrence. View Institutional Ownership Trends for Cumberland Pharmaceuticals. Which institutional investors are selling Cumberland Pharmaceuticals stock? CPIX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. View Insider Buying and Selling for Cumberland Pharmaceuticals. Which institutional investors are buying Cumberland Pharmaceuticals stock? CPIX stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. Company insiders that have bought Cumberland Pharmaceuticals stock in the last two years include Kenneth Krogulski and Michael Bonner. View Insider Buying and Selling for Cumberland Pharmaceuticals. How do I buy shares of Cumberland Pharmaceuticals? Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cumberland Pharmaceuticals' stock price today? One share of CPIX stock can currently be purchased for approximately $6.50. How big of a company is Cumberland Pharmaceuticals? Cumberland Pharmaceuticals has a market capitalization of $100.43 million and generates $40.74 million in revenue each year. The specialty pharmaceutical company earns $-6,960,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. What is Cumberland Pharmaceuticals' official website? The official website for Cumberland Pharmaceuticals is http://www.cumberlandpharma.com. How can I contact Cumberland Pharmaceuticals? Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company can be reached via phone at 615-255-0068 or via email at [email protected] MarketBeat Community Rating for Cumberland Pharmaceuticals (NASDAQ CPIX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 111 (Vote Outperform)Underperform Votes: 129 (Vote Underperform)Total Votes: 240MarketBeat's community ratings are surveys of what our community members think about Cumberland Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPIX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/23/2019 by MarketBeat.com StaffFeatured Article: Do stock splits help investors?